{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:45:27Z","timestamp":1790095527108,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13555-025-01443-w","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:39:15Z","timestamp":1748875155000},"page":"2061-2076","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-2522","authenticated-orcid":false,"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-2674","authenticated-orcid":false,"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-2482","authenticated-orcid":false,"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-4439","authenticated-orcid":false,"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-0100","authenticated-orcid":false,"given":"E. James","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9263-6943","authenticated-orcid":false,"given":"Wan-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-3556","authenticated-orcid":false,"given":"Henrique D.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4205-9579","authenticated-orcid":false,"given":"Tianshuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sancho Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-6433","authenticated-orcid":false,"given":"Brian M.","family":"Calimlim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-6993","authenticated-orcid":false,"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"12","key":"1443_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S Stander","year":"2021","unstructured":"Stander S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343.","journal-title":"N Engl J Med"},{"issue":"3","key":"1443_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583\u201390.","journal-title":"J Invest Dermatol"},{"issue":"Suppl 8","key":"1443_CR3","first-page":"S115","volume":"23","author":"C Avena-Woods","year":"2017","unstructured":"Avena-Woods C. Overview of atopic dermatitis. Am J Manage Care. 2017;23(Suppl 8):S115\u201323.","journal-title":"Am J Manage Care"},{"issue":"4","key":"1443_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1159\/000520159","volume":"183","author":"P Kage","year":"2022","unstructured":"Kage P, Poblotzki L, Zeynalova S, Zarnowski J, Simon JC, Treudler R. Depression, anxiety, and suicidal ideation in patients with atopic eczema in a prospective study in Leipzig, Germany. Int Arch Allergy Immunol. 2022;183(4):409\u201314.","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"1443_CR5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.19457","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Lei D, Yousaf M, et al. What are the best endpoints for eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study. Br J Dermatol. 2021;184(5):888\u201395.","journal-title":"Br J Dermatol"},{"key":"1443_CR6","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/jdv.18995","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, de Bruin-Weller MS, Deleuran M, et al. Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: integrated analysis of three Upadacitinib phase\u00a03 trials. J Eur Acad Dermatol Venereol. 2023;37:1634\u201341.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1443_CR7","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s13555-023-01038-3","volume":"13","author":"H Penton","year":"2023","unstructured":"Penton H, Jayade S, Selveindran S, et al. Assessing response in atopic dermatitis: a systematic review of the psychometric performance of measures used in HTAs and clinical trials. Dermatol Ther (Heidelb). 2023;13(11):2549\u201371.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1443_CR8","doi-asserted-by":"crossref","unstructured":"Silverberg J, Gooderham M, Katoh N, et al. Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy. Br J Dermatol. 2023;188(Suppl 2):Abstract 327.","DOI":"10.1093\/bjd\/ljac140.022"},{"key":"1443_CR9","unstructured":"de Bruin-Weller M, Lauffer F, Criado R, et al. Real-world achievement of atopic dermatitis treat-to-target disease domain criteria: results from a multicountry study. In: Revolutionizing atopic dermatitis (RAD) conference. 2022;Poster number 185."},{"issue":"8","key":"1443_CR10","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jdv.18170","volume":"36","author":"S Stander","year":"2022","unstructured":"Stander S, Bhatia N, Gooderham MJ, et al. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol. 2022;36(8):1308\u201317.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1443_CR11","doi-asserted-by":"publisher","first-page":"adv00830","DOI":"10.2340\/actadv.v102.3932","volume":"102","author":"M Augustin","year":"2022","unstructured":"Augustin M, Costanzo A, Pink A, et al. Real-world treatment patterns and treatment benefits among adult patients with atopic dermatitis: results from the atopic dermatitis patient satisfaction and unmet need survey. Acta Derm Venereol. 2022;102:adv00830.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1443_CR12","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139\u201348.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1443_CR13","unstructured":"RINVOQ\u00ae (upadacitinib). Prescribing information. AbbVie Inc.; 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211675s003lbl.pdf. Accessed 6 July 2023."},{"issue":"10290","key":"1443_CR14","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up\u00a01 and Measure Up\u00a02): results from two replicate double-blind, randomised controlled phase\u00a03 trials. Lancet. 2021;397(10290):2151\u201368.","journal-title":"Lancet"},{"key":"1443_CR15","doi-asserted-by":"crossref","unstructured":"Prajapati VH, Bunick CG, Eyerich K, et al. Sustained improvements over 140\u00a0weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase\u00a03 Measure Up 1 and Measure Up 2 studies. Br J Dermatol. 2024;191(Suppl 2):Abstract 696.","DOI":"10.1093\/bjd\/ljae266.070"},{"key":"1443_CR16","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Guttman-Yassky E, Simpson EL, et al. Efficacy and safety of upadacitinib through 140\u00a0weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase\u00a03 randomized clinical trial results. Br J Dermatol. 2024;190(Suppl 2):Abstract 502.","DOI":"10.1093\/bjd\/ljad498.010"},{"issue":"4","key":"1443_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404\u201313.","journal-title":"JAMA Dermatol"},{"key":"1443_CR18","unstructured":"DUPIXENT\u00ae (dupilumab). Prescribing information. Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology; 2022. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761055s042lbl.pdf. Accessed 3 February 2024."},{"issue":"9","key":"1443_CR19","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1443_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaad.2023.05.033","volume":"89","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase\u00a03, randomized, controlled trial (Heads Up). J Am Acad Dermatol. 2023;89(3):478\u201385.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1443_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/bjd\/ljae404","volume":"192","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Bunick CG, Hong HC, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week\u00a016 results of an open-label randomized efficacy assessor-blinded head-to-head phase\u00a0IIIb\/IV study (Level Up). Br J Dermatol. 2024;192(1):36\u201345.","journal-title":"Br J Dermatol"},{"key":"1443_CR22","unstructured":"European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. Article-20 procedure. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki. Accessed 2 April 2025."},{"issue":"5","key":"1443_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s13555-024-01157-5","volume":"14","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Prajapati VH, Leshem YA, et al. Upadacitinib rapidly improves patient-reported outcomes in atopic dermatitis: 16-week results from phase\u00a03 clinical trials (Measure Up 1 and 2). Dermatol Ther (Heidelb). 2024;14(5):1127\u201344.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1443_CR24","unstructured":"Armstrong AW, Gooderham MJ, St\u00e4nder S, et al. Which signs and symptoms affect the sleep disturbance and quality of life impairment of moderate-to-severe atopic dermatitis? A casual mediation analysis of updacitinib phase 3 Measure Up 1 and 2 studies. Poster presented at the Revolutionizing Atopic Dermatitis (RAD) Conference, Virtual; December 8, 2024"},{"issue":"11","key":"1443_CR25","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/archdermatol.2011.309","volume":"147","author":"ML Schaarschmidt","year":"2011","unstructured":"Schaarschmidt ML, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147(11):1285\u201394.","journal-title":"Arch Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01443-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01443-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01443-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:22:20Z","timestamp":1757182940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01443-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01443-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eric L. Simpson has received personal fees from AbbVie, Amgen, Arcutis Biotherapeutics, Areteia Therapeutics, Boehringer Ingelheim, CorEvitas, Corvus Pharmaceuticals, Dermira, Eli Lilly, Evelo Biosciences, FIDE, Forte Biosciences, Galderma, GSK, Gilead Sciences, Impetus Healthcare, Incyte, Innovaderm Research, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, LEO Pharma, Merck, MJH holding (4\/29\/2021), Numab Therapeutics AG, Pfizer, Physicians World, Prime Pharma, Recludix Pharma, Regeneron, Roivant Sciences, Sanofi-Genzyme, Sitryx Therapeutics, Trevi Therapeutics, and Valeant. He has received grants from or serves as a principal investigator for AbbVie, Acrotech, Amgen, Arcutis Biotherapeutics, ASLAN, Castle Biosciences, CorEvitas, Dermavant, Dermira, Incyte, Kymab, Kyowa Kirin, LEO Pharma, Eli Lilly, Merck, National Jewish Health, Pfizer, Regeneron, Sanofi, TARGET-DERM, and VeriSkin. Jonathan I. Silverberg has served as an advisor, speaker, researcher, or consultant for AbbVie, Asana Biosciences, Dermavant, Galderma, GSK, Glenmark, Kiniksa, LEO Pharma, Lilly, Menlo, Novartis, Pfizer, Realm, and Sanofi\/Regeneron. Vimal H. Prajapati has served as an advisor, consultant, and\/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP\/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipher, CorEvitas, Eczema Society of Canada, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, LEO Pharma, Medexus, Novartis, Organon, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, UCB, and Valeant; has served as an investigator for AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Meiji Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; and has received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Kilian Eyerich has served as a consultant, scientific advisor for, and\/or received research support from AbbVie, Almirall, Bristol Myers Squibb, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB. Norito Katoh has received honoraria as a speaker\/consultant from AbbVie, Celgene Japan, Eli Lilly Japan, Jansen Pharma, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Sanofi, Taiho Pharmaceutical, and Torii Pharmaceutical; and has received grants as an investigator from AbbVie, A2 Healthcare, Boehringer Ingelheim Japan, Eisai, Eli Lilly Japan, Jansen Pharma, Kyowa Kirin, LEO Pharma, Maruho, Sun Pharma, Taiho Pharmaceutical, and Torii Pharmaceutical. Mark Boguniewicz has received research funds (grants paid to the institution) from Regeneron; has been an investigator for Incyte and Sanofi; and has served on advisory boards for AbbVie, Amgen, Dermavant, Eli Lilly, Glaxo, Janssen, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme. Emma Guttman-Yassky is an employee of Mount Sinai; has received research funds (grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boehringer Ingelheim, Cara Therapeutics, Eli Lilly, Galderma, Glenmark\/Ichnos Sciences, Innovaderm, Janssen, KAO, Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Pfizer, Ralexar, Regeneron Pharmaceuticals, and UCB; and has received consulting fees from AbbVie, Almirall, Amgen, Arena, Asana Biosciences, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, LEO Pharma, Pandion Therapeutics, Pfizer, Ribon, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target PharmaSolutions, UCB, and Ventyx Biosciences. E. James Song has served as a speaker, consultant, or investigator for AbbVie, Alumis, Alphyn, Amgen, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, CorEvitas, Dermavant, DermBiont, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, MoonLake, Novartis, Pfizer, Sanofi & Regeneron, Sun Pharma, TARGET PharmaSolutions, TIMBER, and UCB. Wan-Ju Lee, Henrique D. Teixeira, Tianshuang Wu, Cristina Sancho Sanchez, Namita Vigna, and Brian M. Calimlim are full-time employees of AbbVie, and may hold AbbVie stock or stock options. Marjolein de Bruin-Weller has served as a consultant, advisory board member, and\/or speaker for AbbVie, Almirall, Amgen, Galderma, Aslan, Eli Lilly, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As previously reported, Measure Up\u00a01, Measure Up\u00a02, and Heads\u00a0Up were all conducted in accordance with Good Clinical Practice guidelines as defined by the International Conference on Harmonisation, the Declaration of Helsinki, and\/or all applicable federal and local regulations [\n                      \n                      ,\n                      \n                      ]. All three clinical trials were approved by the independent ethics committees or institutional review boards of the investigational centers, as appropriate. Further details regarding ethics approvals can be found in the primary publications for each study [\n                      \n                      ,\n                      \n                      ]. All patients provided written informed consent before screening.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}